Semaglutide# Semaglutide has the most extensive GLP-1 evidence base: SUSTAIN (T2D injectable, 7 trials), PIONEER (T2D oral, 9 trials), STEP (obesity, multiple trials), and SELECT (cardiovascular outcomes, n=17,604, 20% MACE reduction)
Pinto, A
This article presents the figures for Hunner lesions and description of different mucosal lesions after cystoscopic hydrodistension and clearly defines IC/BPS phenotypes according to characteristic cystoscopic findings
What would success look like in 612 months
Since I had such success with Wondr before starting a medication, I have more faith in my abilities
Oral semaglutide represents a major advance in diabetes care, prioritising both glycemic control and heart protection. Based on the SOUL trial data, Novo Nordisk has submitted a label extension application for oral semaglutide